| Phase 17 trials |
|
Phase 1
|
NCT07708272 |
Jul → Dec 2026 expected |
myelofibrosis |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07608666 |
Jul → Dec 2026 expected |
myelofibrosis |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07293390 |
Mar → Apr 2024 |
— |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06024915 |
Sep 2023 → Jan 2024 |
myelofibrosis |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05982106 |
Jul 2021 |
myelofibrosis |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04326348 |
Jul 2020 → Jan 2022 |
hemophagocytic syndrome |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT04339400 |
Nov 2018 → Mar 2023 |
myeloproliferative neoplasm |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 1/23 trials |
|
Phase 1/2
|
NCT06245941 |
May 2024 → Dec 2025 |
myelofibrosis |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT06122831 |
Dec 2023 → Dec 2026 expected |
myelofibrosis |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04941404 |
Jun 2022 → Jul 2023 |
— |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Terminated
|
No outcome recorded
|
| Phase 22 trials |
|
Phase 2
|
NCT07551427 |
Jun 2026 → Jun 2028 expected |
myelofibrosis |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05020652 |
Nov 2021 → Oct 2023 |
myelofibrosis |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|